Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585086 | 0.91 | GAA (0.36) | GAAL3MBTL1ESR1ESR2PTGES | |
| SCHEMBL1701197 | 0.79 | GAA (0.33) | GAAL3MBTL1ESR1ESR2 | |
| SCHEMBL1701016 | 0.75 | GAA (0.35) | GAAL3MBTL1ESR1ESR2 | |
| SCHEMBL12181708 | 0.74 | IL2 (0.45) | GAAL3MBTL1 | |
| SCHEMBL724532 | 0.72 | GAA (0.31) | GAA | |
| SCHEMBL12155820 | 0.71 | IL2 (0.43) | L3MBTL1 | |
| SCHEMBL2592415 | 0.70 | GAA (0.45) | GAAL3MBTL1ESR1ESR2 | |
| SCHEMBL1701645 | 0.69 | MAPT (0.36) | GAAL3MBTL1 | |
| SCHEMBL12181718 | 0.69 | STIM1 (0.52) | GAAL3MBTL1 | |
| SCHEMBL767007 | 0.68 | GAA (0.32) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563759-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-9353099-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-17 | — | — | US | disclosed |
| US-9090612-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754219-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2563759-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011139765-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243366-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | GAA 994/4885L3MBTL1 3943/4885ESR1 2379/4885 |
| US-20130203818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | GAA 994/4885L3MBTL1 3943/4885ESR1 2379/4885 |
| US-20150361075-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | GAA 994/4885L3MBTL1 3943/4885ESR1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.